复发性卵巢上皮癌腹水的个体化治疗

目的：观察个体化治疗对铂类或紫杉类治疗后复发的卵巢癌腹水的近期及远期效果。方法：2004年2月-2006年8月收治铂类或紫杉类药物治疗后复发卵巢上皮癌并腹水患者37例，据不同耐药情况给予尽早腹腔灌注吡柔比星、铂类药物等；适当放腹水、给利尿剂及白蛋白；全身化疗用吉西他滨／依托泊甙（GE）或依托泊甙／环磷酰胺（CE）、多西紫杉醇／卡铂或顺铂（TC或TP）等方案。结果：腹水CR67．57％，PR16.21％，NC16．21％；实体肿瘤CR68．00％，PR16．00%，NC16．00％；患者治疗后生存8—48个月，中位时间19个月；1年生存率81．10％，2年生存率67．57％。血中CA-125浓度与肿瘤复发呈正相关。结论：个体化治疗铂类或紫杉类药物治疗后复发的卵巢癌腹水仍可获效；血CA-125值是提示卵巢癌复发转移特异性及敏感性较强的指标。

Effect of individual treatment of recarrent epithelial ovarian cancer with ascites

Objective：To observe effects of individual chemotherapy and individual intraperitoneal chemotherapy on recrudescent epithelial ovarian cancer with ascites after taxane and platinum treatment. Methods：Individual chem- otherapy and intraperitoneal chemotherapy ,sere administered to 37 recrudescent epithelial ovarian cancer patients with ascites after taxane and platinum treatment. Results：The reactions to individual intraperitoneal chemotherapy of recrudescent epithelial ovarian cancer with ascites were completed response （CR） 67.57% ,partial response （PC） 16.21%, nonresponse （NC） 16.21% ;the reaetiongs of solid turnouts to chemotherapy were （CR） 68.00 %, （PR） 16.00 %, （ NC ） 16.0%. Median overall survival time was 19 months ; 1 - year survival rate 81.10%, 2 - year survival rate 67.57%. Patients serum CA - 125 concentration was a potential prognostic factor positively correlated with tumor relapse and treatment effects. Conclusion： The effects are obvious on recrudescent epithelial ovarian cancer with ascites after taxane and platinum treatment with individual chemotherapy and individual intraperitoneal chemo- therapy ;With a high specificity and sensibility ,serum CA - 125 concentration is an important biomarker to predict treatment effects and prognosis of recrudescent epithelial ovarian cancer with ascites .